Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.

Shirani A, Cross AH, Stuve O

Therapeutic advances in neurological disorders1 Apr 2024Cited by 13 (Europe PMC)

PMID38566910PMCIDPMC10986166DOI10.1177/17562864241241383PepBankPUB-38566910

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyOther
In FAERS reports, dulaglutide was inversely linked to multiple sclerosis reporting.
In plain wordsIn FAERS reports, dulaglutide was linked to lower multiple sclerosis reporting odds.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMultiple sclerosis reporting odds
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Reporting odds ratio
0.165 ratio
dulaglutide
Reporting odds ratio 95% CI
0.109 to 0.248 ratio
dulaglutide
Source sentences
Summary
We found an inverse association between MS and anti-diabetic weight loss-inducing drugs including semaglutide (ROR: 0.238; 95% CI: 0.132-0.429), dulaglutide (ROR: 0.165; 95% CI: 0.109-0.248)
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary analysis of existing data from the FAERS database.
Summary · context
We conducted a disproportionality analysis using the FAERS database between the fourth quarter of 2003 and the second quarter of 2023 to explore associations between MS and weight loss-inducing drugs.
Report a problemFND-3856691001
02HumanObservational studyOther
In FAERS reports, liraglutide was inversely linked to multiple sclerosis reporting.
In plain wordsIn FAERS reports, liraglutide was linked to lower multiple sclerosis reporting odds.
Peptide
Liraglutide
Outcome
DecreaseMultiple sclerosis reporting odds
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Reporting odds ratio
0.161 ratio
liraglutide
Reporting odds ratio 95% CI
0.091 to 0.284 ratio
liraglutide
Source sentences
Summary
liraglutide (ROR: 0.161; 95% CI: 0.091-0.284)
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary analysis of existing data from the FAERS database.
Summary · context
We conducted a disproportionality analysis using the FAERS database between the fourth quarter of 2003 and the second quarter of 2023 to explore associations between MS and weight loss-inducing drugs.
Report a problemFND-3856691002
03HumanObservational studyOther
In FAERS reports, semaglutide was inversely linked to multiple sclerosis reporting.
In plain wordsIn FAERS reports, semaglutide was linked to lower multiple sclerosis reporting odds.
Peptide
Semaglutide
Outcome
DecreaseMultiple sclerosis reporting odds
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Reporting odds ratio
0.238 ratio
semaglutide
Reporting odds ratio 95% CI
0.132 to 0.429 ratio
semaglutide
Source sentences
Summary
We found an inverse association between MS and anti-diabetic weight loss-inducing drugs including semaglutide (ROR: 0.238; 95% CI: 0.132-0.429)
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary analysis of existing data from the FAERS database.
Summary · context
We conducted a disproportionality analysis using the FAERS database between the fourth quarter of 2003 and the second quarter of 2023 to explore associations between MS and weight loss-inducing drugs.
Report a problemFND-3856691003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.

Summary

Results from this study3

Version history

Subjects

Publication types

Keywords